Brief: Kintor Pharma Announces Completion Of Patient Enrollment In Phase II Clinical Trial Of Kx-826 For Treatment Of Androgenetic Alopecia In U.S.
03/08/2022 13:13
Aug 3 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* KINTOR PHARMA ANNOUNCES COMPLETION OF PATIENT ENROLLMENT
IN
PHASE II CLINICAL TRIAL OF KX-826 FOR TREATMENT OF ANDROGENETIC
ALOPECIA IN US
Source text for Eikon: ID:nPnCMgtya
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint